Pharmacokinetics of favipiravir in adults with mild COVID-19 in Thailand

  1. Weerawat Manosuthi
  2. Ing-orn Prasanchaimontri
  3. Suvimol Niyomnaitham
  4. Rujipas Sirijatuphat
  5. Lantharita Charoenpong
  6. Katherine Copeland
  7. Tim R. Cressey
  8. Phongpan Mokmued
  9. Kulkanya Chokephaibulkit
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

We assessed the pharmacokinetics of favipiravir (FPV) in adults with symptomatic SARS-CoV-2 infection without pneumonia in Thailand. FPV dosing was 1800 mg twice-daily on day 1, then 800 mg twice-daily for 14 days. Eight subjects (7 female), median (range) age 39 (19-53) years and BMI 27.9 (18.0-33.6) were included. Inter-subject variability was high but all achieved minimum plasma concentrations (Cmin) above EC50(9.7 mg/L). FPV was well tolerated; 1 subject stopped prematurely due to rash.

Related articles

Related articles are currently not available for this article.